MedTrace Logo

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

NCT04072315 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-12-12

Study results available
· View outcomes & findings →

Summary

A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.

Conditions

Interventions

DRUG

PLN-74809

PLN-74809

RADIATION

Knottin tracer

Radiotracer

Sponsors & Collaborators

Principal Investigators

  • Pliant Therapeutics Medical Monitor · Pliant Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-13
Primary Completion
2022-06-27
Completion
2022-07-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04072315 on ClinicalTrials.gov